Literature DB >> 1845774

Prophylaxis of uric acid stones with alternate day doses of alkaline potassium salts.

J S Rodman1.   

Abstract

Uric acid stone formation ordinarily is prevented by increases in the urinary pH after meals. This postprandial alkaline tide is lost in patients who make such calculi. Single dose, alternate day administration of an alkaline potassium salt will increase urinary pH and simulate this normal physiological mechanism. An important part of the regimen is patient self-monitoring to verify that the urinary pH increases to greater than 6.8, 1 1/2 to 2 hours after the medication is taken. In contrast to multiple dose daily regimens, this mode of base administration is tolerated better and easier to follow. In 17 patients, 7 with the recurrent gravel/colic syndrome and 10 with prior stones, this regimen abolished calculus formation during an average followup of 2 1/2 years. However, further studies are needed before this regimen can be recommended as standard therapy for uric acid stone prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845774     DOI: 10.1016/s0022-5347(17)38258-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

Review 1.  Pharmacotherapy of urolithiasis: evidence from clinical trials.

Authors:  Orson W Moe; Margaret S Pearle; Khashayar Sakhaee
Journal:  Kidney Int       Date:  2010-10-06       Impact factor: 10.612

Review 2.  [Evidence-based pharmacological metaphylaxis of stone disease].

Authors:  M Straub; R E Hautmann
Journal:  Urologe A       Date:  2006-11       Impact factor: 0.639

3.  Evolution of lithogenic urinary parameters with a low dose potassium citrate treatment.

Authors:  F Grases; A Conte; J G March; L García-Ferragut
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 4.  Update on the pathophysiology and management of uric acid renal stones.

Authors:  Jon-Emile S Kenny; David S Goldfarb
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

5.  Uric Acid Nephrolithiasis: A Systemic Metabolic Disorder.

Authors:  Michael R Wiederkehr; Orson W Moe
Journal:  Clin Rev Bone Miner Metab       Date:  2011-12

6.  Deletion of the Cl-/HCO3- exchanger pendrin downregulates calcium-absorbing proteins in the kidney and causes calcium wasting.

Authors:  Sharon Barone; Hassane Amlal; Jie Xu; Manoocher Soleimani
Journal:  Nephrol Dial Transplant       Date:  2011-08-26       Impact factor: 5.992

Review 7.  Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline.

Authors:  M Straub; W L Strohmaier; W Berg; B Beck; B Hoppe; N Laube; S Lahme; M Schmidt; A Hesse; K U Koehrmann
Journal:  World J Urol       Date:  2005-11-29       Impact factor: 4.226

Review 8.  Preventive treatment of nephrolithiasis with alkali citrate--a critical review.

Authors:  D Mattle; B Hess
Journal:  Urol Res       Date:  2005-05-04

Review 9.  Treatment of patients with uric acid stones.

Authors:  Ita Pfeferman Heilberg
Journal:  Urolithiasis       Date:  2015-12-08       Impact factor: 3.436

Review 10.  Method of alkalization and monitoring of urinary pH for prevention of recurrent uric acid urolithiasis: a systematic review.

Authors:  Guido Maarten Kamphuis; Jons Wouter van Hattum; Prim de Bie; Bhaskar K Somani
Journal:  Transl Androl Urol       Date:  2019-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.